Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | TDO2 | P48775 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4428258 | 0.83 | ALDH1A1 (0.46) | IDO1TDO2CES2CES1ACHE | |
| SCHEMBL127093 | 0.81 | IDO1 (0.41) | IDO1TDO2CES2CES1ACHE | |
| SCHEMBL30846983 | 0.79 | P2RX7 (0.42) | IDO1TDO2CES2CES1ACHE | |
| SCHEMBL5792453 | 0.79 | IDO1 (0.39) | IDO1TDO2CES2CES1ACHE | |
| SCHEMBL17289093 | 0.79 | IDO1 (0.39) | IDO1TDO2CES2CES1ACHE | |
| SCHEMBL3310094 | 0.79 | CES2 (0.46) | IDO1TDO2CES2CES1ALDH1A1 | |
| SCHEMBL28329280 | 0.79 | IDO1 (0.39) | IDO1TDO2CES2CES1ACHE | |
| SCHEMBL626283 | 0.79 | P2RX7 (0.42) | IDO1TDO2CES2CES1ACHE | |
| SCHEMBL655520 | 0.78 | CYP1A2 (0.43) | IDO1TDO2CES2CES1CYP3A4 | |
| SCHEMBL3454906 | 0.77 | IDO1 (0.42) | IDO1TDO2CES2CES1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108299435-A | 13- ethanol amine matrine derivatives prepare and its application | 广西大学 | 2018-07-20 | — | — | CN | claimed |
| EP-3510032-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | Incyte Corporation (US) | 2019-07-17 | — | — | EP | disclosed |
| CN-105263927-B | Inhibitors of glutaminyl cyclase | 前体生物药物股份公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-109069491-A | The positive allosteric modulators of mAChR M1 | 范德比尔特大学 | 2018-12-21 | — | — | CN | disclosed |
| CN-108218849-A | New inhibitor | 前体生物药物股份公司 | 2018-06-29 | — | — | CN | disclosed |
| WO-2018049200-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-03-15 | — | — | WO | disclosed |
| CN-107001362-A | Heteroaryl compound as BTK inhibitor and application thereof | 默克专利有限公司 | 2017-08-01 | — | — | CN | disclosed |
| CN-105504232-B | The new method of copolymer is prepared based on two kinds of different carbon radicals co-coupling reactions | 浙江大学 | 2017-07-18 | — | — | CN | disclosed |
| CN-103492385-B | Be used for the treatment of the noval chemical compound of degenerative disease and inflammatory disease | GALAPAGOS N.V. (BE) | 2016-05-11 | — | — | CN | disclosed |
| CN-102781884-B | Process for producing alpha-olefin oligomer | MITSUBISHI CHEMICAL CORP. (JP) | 2015-11-25 | — | — | CN | disclosed |
| US-7138400-B2 | Sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-21 | — | — | US | disclosed |
| WO-2006082001-A1 | HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-10 | — | — | WO | disclosed |
| US-20060178381-A1 | Heterocyclic-substituted phenyl methanones | HOFFMANN-LA ROCHE INC. | 2006-08-10 | — | — | US | disclosed |
| EP-1334085-B1 | SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME (GB) | 2005-08-24 | — | — | EP | disclosed |
| US-20040049038-A1 | Sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2004-03-11 | — | — | US | disclosed |
| EP-1334085-A1 | SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME LTD. (GB) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002036555-A1 | SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-05-10 | — | — | WO | disclosed |
| US-5698580-A | TREATING DISEASES CAUSED BY RESPIRATORY SYNCYTIAL VIRUS | RATIONAL DRUG DESIGN LABORATORIES (JP) | 1997-12-16 | — | — | US | disclosed |
| EP-0770609-A1 | ANTIVIRAL AGENT CONTAINING BENZODITHIIN DERIVATIVE AS ACTIVE INGREDIENT | Rational Drug Design Laboratories (JP) | 1997-05-02 | — | — | EP | disclosed |
| US-5298622-A | Spiroindane opiate analogs | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1994-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178381-A1 | Heterocyclic-substituted phenyl methanones | CYP2B6, CYP2D6, CYP1A2 | IDO1 2950/4885TDO2 1117/4885CES2 2259/4885 |
| US-20040049038-A1 | Sulfamides as gamma-secretase inhibitors | BACE1, BACE2, PSEN1 | IDO1 3070/4885TDO2 3826/4885CES2 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.